Omeros Corporation

Company Overview

Business Model: Omeros Corporation is an innovative, commercial-stage biotechnology company focused on discovering and developing first-in-class protein and small-molecule therapeutics. The company targets large-market and orphan indications, with a primary emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Revenue generation is expected from product sales (YARTEMLEA ® (narsoplimab-wuug) launched in January 2026), milestone payments, and royalties from partnered programs (e.g., zaltenibart with Novo Nordisk Health Care AG), and interest income.

Market Position: Omeros Corporation is a worldwide leader in complement science. Its commercial product, YARTEMLEA, is the first and only FDA-approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”), positioning it uniquely in this orphan indication. The company holds exclusive global rights to MASP-2 inhibitors and has a partnered MASP-3 inhibitor (zaltenibart) with Novo Nordisk Health Care AG, which is a first-in-class, late-stage clinical humanized monoclonal antibody targeting the alternative pathway of the complement system.

Recent Strategic Developments:

• YARTEMLEA FDA Approval: YARTEMLEA (narsoplimab-wuug) received U.S. Food and Drug Administration (“FDA”) approval on December 23, 2025, for the treatment of TA-TMA in adult and pediatric patients aged two years and older. Commercial distribution and sales commenced in January 2026.
• Zaltenibart Partnership with Novo Nordisk Health Care AG: On November 25, 2025, Omeros Corporation completed a transaction with Novo Nordisk Health Care AG, granting Novo Nordisk Health Care AG exclusive global rights to develop and commercialize zaltenibart (formerly OMS906) and related compounds. Omeros Corporation received an upfront cash payment of $240.0 million and is eligible for up to $510.0 million in development and approval milestones, and up to $1.3 billion in sales-based milestones, plus tiered royalties on net sales.
• Debt Restructuring and Repayment: In November 2025, Omeros Corporation fully repaid its $67.1 million Term Loan, which was secured in June 2024, using proceeds from the zaltenibart transaction. The company also exchanged $70.8 million of its 2026 Notes for newly-issued 2029 Notes and converted $10.0 million of 2026 Notes into common stock in May 2025. The remaining $17.1 million of 2026 Notes were repaid at maturity in February 2026.
• New Share Repurchase Program: On November 29, 2025, the Board of Directors approved a new share repurchase program authorizing up to $100.0 million of common stock repurchases.

Geographic Footprint: Omeros Corporation's principal executive offices and laboratory space are located in Seattle, Washington, U.S. YARTEMLEA is approved for commercialization in the U.S., with commercial distribution and sales beginning in January 2026. A marketing authorization application for YARTEMLEA in TA-TMA has been submitted to the European Medicines Agency (“EMA”) and is under review for potential marketing authorization across EU member states and European Economic Area countries. The company is evaluating potential partnerships for ex-U.S. commercialization of YARTEMLEA.

Financial Performance

Revenue Analysis

(Note: Omeros Corporation did not generate product sales revenue from continuing operations in 2025 or 2024, as its commercial product YARTEMLEA launched in January 2026. The primary income source for continuing operations in 2025 was a one-time gain from an asset sale.)

Profitability Metrics:

• Gross Margin: Not applicable (no traditional gross profit from product sales in continuing operations for 2025/2024).
• Operating Margin: Not applicable (operating loss reported before other income/gains).
• Net Margin: Not applicable (net loss reported before other income/gains).

Investment in Growth:

• R&D Expenditure: $81.3 million (33.6% of Total Income from Continuing Operations, including gain on sale of zaltenibart)
• Capital Expenditures: $0.065 million
• Strategic Investments: Omeros Corporation received an upfront cash payment of $240.0 million from Novo Nordisk Health Care AG for the sale of zaltenibart. The company's internal investments are primarily in R&D programs.

Business Segment Analysis

Omeros Corporation operates in one business segment focused on the research, discovery, development, and commercialization of therapeutics. While not formally segmented, the company's pipeline is diversified across several key programs:

YARTEMLEA (narsoplimab-wuug)

Financial Performance:

• Revenue: Commercial sales commenced in January 2026, therefore no revenue from YARTEMLEA was recorded in 2025 or prior periods.
• Operating Margin: Not applicable.
• Key Growth Drivers: FDA approval for TA-TMA in December 2025, making it the first and only approved therapy for this indication. Ongoing review of a marketing authorization application by the European Medicines Agency. Potential for label expansion in TA-TMA and development in other indications like Acute Respiratory Distress Syndrome (“ARDS”).

Product Portfolio:

• YARTEMLEA (narsoplimab-wuug): A proprietary, patented human monoclonal antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement. Approved for TA-TMA in adult and pediatric patients aged two years and older.
• New product launches or major updates: Commercial launch in the U.S. in January 2026.

Market Dynamics:

• Competitive positioning within segment: YARTEMLEA is currently the only approved treatment for TA-TMA. However, it may face competition from continued off-label use of C5 inhibitors like Soliris ® (eculizumab) and Ultomiris ® (ravulizumab-cwvz).
• Key customer types and market trends: Focus on transplant centers across the U.S., with initial prioritization of centers with high transplant volume and established TA-TMA expertise.

Zaltenibart (formerly OMS906)

Financial Performance:

• Revenue: Omeros Corporation received an upfront cash payment of $240.0 million from Novo Nordisk Health Care AG in November 2025 for the exclusive global rights to develop and commercialize zaltenibart.
• Operating Margin: Not applicable.
• Key Growth Drivers: Potential for up to $510.0 million in development and approval milestone payments and up to $1.3 billion in sales-based milestone payments from Novo Nordisk Health Care AG, plus tiered royalties on annual net sales.

Product Portfolio:

• Zaltenibart: A first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3, the key activator of the alternative pathway of the complement system.
• New product launches or major updates: Exclusive global rights transferred to Novo Nordisk Health Care AG for development and commercialization.

Market Dynamics:

• Competitive positioning within segment: Zaltenibart has shown multiple potential advantages over other alternative pathway inhibitors in development and on the market.
• Key customer types and market trends: Potential applications across a broad range of therapeutic areas and indications, including paroxysmal nocturnal hemoglobinuria (PNH), renal diseases (e.g., immunoglobulin A nephropathy (IgAN), C3 glomerulopathy, atypical hemolytic uremic syndrome), and other immune and complement-driven disorders.

OMS1029 (MASP-2 / Lectin Pathway)

Financial Performance:

• Revenue: Not yet commercialized.
• Operating Margin: Not applicable.
• Key Growth Drivers: Long-acting second-generation antibody targeting MASP-2, designed for chronic indications with convenient once-quarterly, subcutaneous administration. Phase 1 studies completed with good tolerability.

Product Portfolio:

• OMS1029: A long-acting antibody targeting MASP-2, intended to complement YARTEMLEA.

Market Dynamics:

• Competitive positioning within segment: Intended for chronic indications, potentially competing with other complement inhibitors if approved for similar uses.

OMS527 (PDE7)

Financial Performance:

• Revenue: Not yet commercialized.
• Operating Margin: Not applicable.
• Key Growth Drivers: Lead orally administered PDE7 inhibitor compound for cocaine use disorder (“CUD”), supported by a $6.24 million grant from the National Institute on Drug Abuse (“NIDA”). Preclinical studies completed, supporting an in-patient human study. Also being evaluated for Levodopa-induced dyskinesia (“LID”) in Parkinson’s disease.

Product Portfolio:

• OMS527: Multiple PDE7 inhibitor compounds based on discoveries linking PDE7 to addiction, compulsive disorders, and movement disorders.

Market Dynamics:

• Competitive positioning within segment: Novel approach to CUD and LID, addressing significant unmet medical needs.

OncotoX-AML

Financial Performance:

• Revenue: Preclinical stage.
• Operating Margin: Not applicable.
• Key Growth Drivers: Novel oncology program developing large molecule therapeutics to selectively target and kill dividing cancer cells. Drug development candidate selected, with IND-enabling studies underway for Acute Myeloid Leukemia (“AML”). Preclinical data show superior efficacy and good tolerability compared to current AML standard of care.

Product Portfolio:

• OncotoX-AML: Engineered biologic designed to selectively kill AML blasts and relapse-related leukemia stem cells, with a mechanism independent of common genetic mutations.

Market Dynamics:

• Competitive positioning within segment: Addresses limitations of current AML treatments (high relapse rates, substantial side effects) with a unique mechanism of action.

Targeted Complement Activating Therapy (T-CAT)

Financial Performance:

• Revenue: Preclinical stage.
• Operating Margin: Not applicable.
• Key Growth Drivers: New class of recombinant antibodies for broad action against multidrug-resistant organisms (“MDROs”), designed to harness complement activation to kill pathogens directly. Preclinical animal data demonstrate effectiveness against life-threatening Gram-negative and Gram-positive bacteria.

Product Portfolio:

• T-CAT platform: Recombinant antibodies for infectious disease treatment.

Market Dynamics:

• Competitive positioning within segment: Addresses urgent unmet needs in MDRO therapies without contributing to drug resistance.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: A new share repurchase program was approved on November 29, 2025, authorizing repurchases of up to $100.0 million of common stock. No shares were repurchased in 2025. In 2024, 3.2 million shares were repurchased for $11.9 million, and in 2023, 1.8 million shares were repurchased for $4.7 million.
• Dividend Payments: Omeros Corporation has never declared or paid any cash dividends on its capital stock and does not anticipate paying dividends in the foreseeable future.
• Dividend Yield: 0.0%
• Future Capital Return Commitments: A $100.0 million share repurchase program is authorized.

Balance Sheet Position:

• Cash and Equivalents: $9.7 million (as of December 31, 2025)
• Total Debt: $87.9 million (as of December 31, 2025), a 46.7% decrease from $164.9 million at December 31, 2024.
• Net Cash Position: $83.9 million (Cash, Cash Equivalents & Short-term Investments of $171.8 million minus Total Debt of $87.9 million as of December 31, 2025).
• Credit Rating: Not disclosed.
• Debt Maturity Profile:
  • 2026 Notes: $17.1 million aggregate principal amount outstanding as of December 31, 2025, repaid in full upon maturity in February 2026.
  • 2029 Notes: $70.8 million aggregate principal amount outstanding, maturing on June 15, 2029. Interest rate of 9.50% per annum, payable semi-annually.

Cash Flow Generation:

• Operating Cash Flow: $(116.1) million (for the year ended December 31, 2025)
• Free Cash Flow: $(116.2) million (Operating Cash Flow of $(116.1) million minus Capital Expenditures of $0.065 million for 2025)
• Cash Conversion Metrics: Not explicitly disclosed, but the company's net cash used in operating activities decreased by $32.7 million in 2025 compared to 2024, primarily due to a decrease in net loss and non-cash charges, partially offset by the gain on sale of zaltenibart.

Operational Excellence

Production & Service Model: Omeros Corporation does not own or operate internal manufacturing facilities for commercial or clinical supplies. It relies solely on third-party contract manufacturers for producing YARTEMLEA and its product candidates under current Good Manufacturing Practices (“cGMP”). The company has in-house laboratories for analytical method development, bioanalytical testing, formulation, non-GMP stability testing, and small-scale compounding.

Supply Chain Architecture: Key Suppliers & Partners:

• Commercial Production (YARTEMLEA drug substance): Lonza Biologics Tuas Pte. Ltd. - manufactures YARTEMLEA drug substance under a master services agreement (initial term expires five years after first commercial sale in U.S. or EU).
• Commercial Production (YARTEMLEA finished drug product): Vetter Pharma International, GmbH - aseptically fills YARTEMLEA in vials for clinical or commercial use under a Combined Development and Commercial Supply Agreement (initial term expires five years after first commercial sale).
• Labeling and Final Packaging (YARTEMLEA): A third-party vendor is utilized.
• Product Candidates Manufacturing: Relies on various contract manufacturers for preclinical and clinical supplies, storage, and distribution.
• Zaltenibart Transition: Under a Transition Services Agreement, Omeros Corporation is transitioning agreements and relationships with third-party manufacturers, storers, and distributors of zaltenibart to Novo Nordisk Health Care AG.

Facility Network:

• Principal Office and Laboratory: Approximately 106,949 square feet in Seattle, Washington (the Omeros Building), including 1,134 square feet subleased to third parties. Lease term through November 2027, with two five-year extension options.
• Manufacturing: No internal manufacturing facilities.
• Research & Development: In-house laboratories for analytical method development, bioanalytical testing, formulation, non-GMP stability testing, and small-scale compounding.

Operational Metrics: Not explicitly disclosed (e.g., capacity utilization, efficiency measures, quality indicators).

Market Access & Customer Relationships

Go-to-Market Strategy: Omeros Corporation has retained all worldwide marketing and distribution rights to YARTEMLEA and its product candidates (excluding zaltenibart). The company plans to market and sell independently, through third-party arrangements, or a combination.

Distribution Channels:

• Direct Sales: For YARTEMLEA in the U.S. market, Omeros Corporation has deployed a field force of account managers and directors, market development managers, access leads, and medical science liaisons to engage directly with transplant centers.
• Channel Partners: Evaluating potential partnerships for commercialization of YARTEMLEA outside the U.S. (both broad ex-U.S. and regional collaborations).
• Digital Platforms: Not explicitly detailed.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Initial commercialization efforts for YARTEMLEA prioritize transplant centers with the greatest transplant volume and established TA-TMA expertise (top 80 of 175 U.S. centers represent ~80% of procedures).
• Strategic Partnerships: Novo Nordisk Health Care AG for zaltenibart; Daiichi Sankyo Co., Ltd. for PDE7 inhibitors.
• Customer Concentration: Not explicitly detailed for YARTEMLEA, but the focus on a limited number of transplant centers suggests potential concentration.

Geographic Revenue Distribution:

• U.S.: Primary focus for YARTEMLEA commercialization.
• Ex-U.S.: Marketing authorization application for YARTEMLEA under review by the EMA. Omeros Corporation retains rights to receive royalties on ex-U.S. net sales of OMIDRIA, which have not been significant to date.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical and biotechnology industry is highly competitive, characterized by established large pharmaceutical and biotechnology companies, as well as smaller companies. It involves extensive government regulation, significant R&D investment, and complex intellectual property landscapes. Industry Characteristics: The pharmaceutical and biotechnology industry is highly competitive and characterized by a number of established, large pharmaceutical and biotechnology companies as well as smaller companies.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• C5 Inhibitors (e.g., Soliris ® (eculizumab), Ultomiris ® (ravulizumab-cwvz)): Historically used off-label for TA-TMA. Ravulizumab Phase 3 trials in pediatric TA-TMA did not meet primary endpoint; adult trial results not announced.
• Other Complement-Targeted Therapeutics (e.g., Empaveli ® (pegcetacoplan), Tavneos ® (avocopan), PiaSky ® (crovalimab-akkz), Voydeya (danicopan), Fabhalta ® (iptacopan)): These are either on the market or in advanced clinical development and could compete with YARTEMLEA, OMS1029, or other complement-targeting candidates if approved for similar indications or used off-label.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in complement-mediated diseases, cancers, and addictive disorders.

Competitive Response Strategy: Omeros Corporation aims to maintain competitive advantage through its first-in-class product (YARTEMLEA), diversified pipeline, and strong intellectual property portfolio.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Lack of Acceptance: Risk of YARTEMLEA not being accepted by physicians, patients, or third-party payers.
• Competition: YARTEMLEA faces competition from continued off-label use of other complement inhibitors and potential future approvals of competing products for TA-TMA.
• Pricing and Reimbursement: Success of YARTEMLEA depends heavily on adequate coverage and reimbursement from government and private payers, which are increasingly challenging prices and examining cost-effectiveness.
• Economic Weakness: Inflation or political instability in foreign markets could adversely affect international operations.
• Policy Actions: Changes in U.S. federal government policies (e.g., tariffs, healthcare reforms like the Inflation Reduction Act) could increase production costs, disrupt supply chains, or reduce competitiveness.
• Product Liability: Inherent risk of product liability claims, which could damage reputation and harm business if insurance is inadequate.

Technology Disruption:

• AI Risks: Use of artificial intelligence exposes the company to deficient outputs, unintentional disclosures of sensitive data, and an evolving regulatory landscape, potentially harming intellectual property, competitive position, and reputation.
• Innovation Pipeline: Risk that product candidates may not successfully complete clinical development, be suitable for commercialization, or generate revenue through partnerships. Preclinical programs may not produce suitable candidates for clinical trials.

Customer Concentration: Not explicitly detailed as a risk, but the focus on a limited number of transplant centers for YARTEMLEA could imply concentration risk.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Third-Party Manufacturing Reliance: Sole reliance on third-party manufacturers for commercial and clinical supplies of YARTEMLEA and product candidates. Risks include inability to secure arrangements on commercially reasonable terms, manufacturing delays, failure to meet regulatory requirements (cGMP), and potential for product recalls or shortages.
• Supplier Dependency: Reliance on third-party suppliers for APIs, excipients, test kits, and other raw materials. Risks include unavailability, untimely delivery, or insufficient quantities, which could adversely affect sales or development.
• Transition Services Agreement: Obligations under the Transition Services Agreement with Novo Nordisk Health Care AG require significant internal resources, potentially diverting management time and personnel from other programs.

Geographic Concentration:

• International Operations: Risks associated with marketing products outside the U.S., including reduced intellectual property protection, unexpected changes in tariffs or trade barriers, economic weakness, foreign currency fluctuations, and geopolitical events.

Capacity Constraints:

• Manufacturing Capacity: Limited and unpredictable supply of contract manufacturing capacity, especially for biologic drug products.

Financial & Regulatory Risks

Market & Financial Risks:

• Operating Losses: Cumulative operating losses since inception; continued substantial cash burn for R&D, commercialization, and debt service. Inability to raise additional capital could delay or discontinue development programs.
• Indebtedness: Existing debt ($87.9 million as of December 31, 2025) and future indebtedness could limit cash flow, restrict additional financing, and increase vulnerability to adverse economic conditions.
• Stock Price Volatility: Highly volatile stock price due to numerous factors, including operating performance, market conditions, and potential dilution from equity issuances.
• OMIDRIA Royalty Dependence: Realization of future value from OMIDRIA royalties depends on Rayner Surgical, Inc.'s net sales and may be less than anticipated.
• Zaltenibart Value Dependence: Realization of future value from zaltenibart depends on Novo Nordisk Health Care AG's successful development, regulatory approval, and commercialization efforts, which are outside Omeros Corporation's control.
• Embedded Derivatives: Swings in stock price or changes in interest rates could significantly affect the valuation of the 2029 Notes conversion derivative, leading to non-cash losses or gains.

Regulatory & Compliance Risks:

• Extensive Government Regulation: Subject to extensive regulation by U.S. and foreign authorities (FDA, EMA) covering all aspects of drug development, manufacturing, marketing, and sales. Failure to comply can result in severe sanctions, delays, or withdrawal of approvals.
• Post-Marketing Requirements: Failure to comply with YARTEMLEA post-marketing requirements (e.g., safety registry, pediatric PK/PD study, CMC) could lead to regulatory actions, labeling changes, or withdrawal of approval.
• Regulatory Delays: Clinical trials and regulatory approvals are subject to expected and unforeseen delays, increasing costs and delaying revenue generation.
• Healthcare Compliance Laws: Subject to federal and state healthcare compliance laws (e.g., Anti-Kickback Statute, False Claims Act, Sunshine Act) and similar foreign laws. Violations can lead to significant penalties and exclusion from healthcare programs.
• Hatch-Waxman Act / Biosimilars: Competition from generic or biosimilar versions of products, which can be approved through abbreviated pathways, potentially reducing market exclusivity and profitability.

Legal Proceedings:

• Intellectual Property Litigation: Risk of costly and time-consuming patent infringement lawsuits, potentially leading to injunctions, damages, or invalidation of patents.
• Commercial Disputes: Risk of disputes, claims, or litigation related to commercial contractual arrangements.

Geopolitical & External Risks

Geopolitical Exposure:

• International Operations: Business interruptions from geopolitical events, natural disasters, or outbreaks of contagious disease (e.g., COVID-19 previously slowed enrollment).
• Trade Relations: Impact of broad imposition of tariffs or other policy actions by the U.S. administration on production costs, supply chain, and competitiveness.

Sanctions & Export Controls: Not explicitly detailed as a specific risk category, but mentioned within general regulatory compliance.

Innovation & Technology Leadership

Research & Development Focus: Omeros Corporation maintains a robust R&D organization with expertise in discovery research, preclinical development, product formulation, analytical and medicinal chemistry, manufacturing, clinical development, and regulatory and quality assurance. Core Technology Areas:

• Complement System Modulation: Worldwide leader in complement science, focusing on lectin and alternative pathways. Developing inhibitors of mannan-binding lectin-associated serine protease 2 (“MASP-2”) and MASP-3.
• PDE7 Inhibition: Discoveries linking PDE7 to addiction, compulsive disorders, and movement disorders.
• Oncology: Novel oncology program developing large molecule therapeutics to selectively target and kill dividing cancer cells (OncotoX-AML).
• Targeted Complement Activating Therapy (T-CAT): Platform for recombinant antibodies against multidrug-resistant organisms.

Innovation Pipeline:

• Narsoplimab: Continued clinical development to expand on the approved label in TA-TMA and for other indications like ARDS.
• OMS1029: Long-acting MASP-2 inhibitor, completed Phase 1, finalizing indication for Phase 2 in chronic conditions.
• OMS527: Lead orally administered PDE7 inhibitor in Phase 1b for CUD (NIDA-funded), also evaluating for LID.
• MASP-2 Small-Molecule Inhibitors: In final stage of selecting a drug development candidate.
• MASP-3 Small-Molecule Inhibitors: Assessing molecules to select a drug development candidate.
• OncotoX-AML: IND-enabling studies underway, goal to enter clinic by late 2027.
• T-CAT: Conducting animal studies to select a drug development candidate for clinical trials.

Intellectual Property Portfolio:

• Patent Strategy: Owns or holds worldwide exclusive licenses to issued patents and pending patent applications. Decisions on foreign patent protection are based on resources, market size, competitor presence, and enforcement effectiveness.
• MASP-2 Program (YARTEMLEA & OMS1029): Patents expire as late as 2037, with pending applications potentially extending to 2042.
• MASP-3 Program: Retains certain patent applications for grandfathered MASP-3 program (unrelated to zaltenibart), with pending applications potentially extending to 2046. Holds licenses from Novo Nordisk Health Care AG.
• PDE7 Program (OMS527): Patents expire as late as 2031 (U.S.) and 2033 (Europe), with pending applications potentially extending to 2044. Holds exclusive licenses from Daiichi Sankyo Co., Ltd.
• Oncology Program: Patent applications potentially extending to 2046.
• T-CAT Program: Patents expire as late as 2042, with pending applications potentially extending to 2046.
• Trademark Strategy: Registered and maintains "OMEROS" and "YARTEMLEA" trademarks in the U.S. and foreign jurisdictions.
• IP Litigation: No material claims of infringement or other challenges to trademarks.

Technology Partnerships:

• Novo Nordisk Health Care AG: Exclusive global rights to zaltenibart.
• Daiichi Sankyo Co., Ltd.: Exclusive worldwide license for PDE7 inhibitors for movement, addiction, and compulsive disorders.
• NIDA (National Institutes of Health): Grant funding for OMS527 development in cocaine use disorder.
• Emory University: Collaboration for evaluating OMS527 for Levodopa-induced dyskinesia.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's success depends significantly on the continued contributions of its management team.

Board Composition: The filing lists the names of the directors but does not provide details on their independence, expertise areas, or committee structure.

Human Capital Strategy

Workforce Composition:

• Total Employees: 175 full-time employees (as of December 31, 2025).
• Geographic Distribution: Not explicitly detailed, but principal offices are in Seattle, Washington.
• Skill Mix:
  • Research & Development: 116 employees (38 with Ph.D.s, 4 with M.D.s).
  • Sales & Marketing: 15 employees.
  • Finance, Legal, Business Development & Administration: 44 employees.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Maintains a rigorous, highly selective, and time-consuming hiring process.
• Retention Metrics: Not explicitly disclosed.
• Employee Value Proposition: Not explicitly detailed beyond compensation philosophy and benefits.

Diversity & Development:

• Diversity Metrics: Not explicitly disclosed.
• Development Programs: Not explicitly detailed.
• Culture & Engagement: Considers employee relations to be good. None of the employees are represented by a labor union.

Regulatory Environment & Compliance

Regulatory Framework: Omeros Corporation is subject to extensive regulation by government authorities in the U.S. (FDA) and the European Union (EMA), covering research, development, testing, manufacturing, labeling, promotion, advertising, distribution, marketing, and export/import of drug and biologic products. Industry-Specific Regulations:

• FDA Approval Process: Requires formulation and manufacturing process development, preclinical testing, submission of an Investigational New Drug (“IND”) application, adequate and well-controlled human clinical trials (Phase 1, 2, 3), stability assessment, and submission of a New Drug Application (“NDA”) or Biologics License Application (“BLA”).
• EMA Approval Process: Requires submission of a Clinical Trial Application (“CTA”) and a Marketing Authorization Application (“MAA”) for review, potentially under a centralized procedure for EU-wide marketing authorization.
• Post-Marketing Requirements: Ongoing regulatory oversight, including pharmacovigilance, adverse event reporting, cGMP compliance, advertising/promotion restrictions, and potential post-marketing studies or Risk Evaluation and Mitigation Strategies (“REMS”). YARTEMLEA has post-marketing requirements for a safety registry and commitments for a pediatric PK/PD study and CMC.
• Fast-Track, Priority Review, Breakthrough Therapy, Accelerated Approval: Omeros Corporation's product candidates may be eligible for these designations to expedite development and review, but they do not alter standard regulatory requirements.
• Orphan Drug Designation: Narsoplimab has received orphan medicinal product designation from the European Commission for hematopoietic stem cell transplantation.
• Pediatric Testing and Exclusivity: Subject to mandatory pediatric testing requirements and voluntary incentives for exclusivity in the U.S. and similar requirements in the EU.

Trade & Export Controls:

• Drug Supply Chain Security Act (“DSCSA”): Imposes obligations on manufacturers for product tracking and tracing, serialization, verification requests, and record-keeping. Similar anti-counterfeiting and serialization requirements exist in the EU.
• Export Restrictions: Not explicitly detailed as a specific risk, but compliance with international regulations is mentioned.
• Sanctions Compliance: Not explicitly detailed as a specific risk, but compliance with international regulations is mentioned.

Legal Proceedings: As of the filing date, Omeros Corporation was not involved in any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 72.0% (2025), 1.3% (2024), 0.0% (2023).
• Geographic Tax Planning: Income is wholly derived from domestic U.S. operations; no income from foreign subsidiaries.
• Tax Reform Impact: The One Big Beautiful Bill Act (“OBBBA”), enacted July 4, 2025, allows for immediate expensing of domestic research and development expenditures for tax years beginning after December 31, 2024, reversing a prior capitalization requirement. This reduced federal taxable income to zero for 2025. Foreign R&D expenditures remain subject to capitalization.
• NOL Carryforwards:
  • U.S. Federal: Approximately $386.5 million as of December 31, 2025. Pre-2018 NOLs ($45.4 million) expire between 2036 and 2037. Post-2018 NOLs ($340.9 million) do not expire but are limited to 80% of current year taxable income.
  • State: Approximately $229.8 million as of December 31, 2025.
• Research and Development Tax Credit Carryforwards: $111.8 million, expiring between 2026 and 2044.
• Valuation Allowance: Maintains a full valuation allowance on its net U.S. deferred tax assets due to cumulative and forecasted near-term losses.
• Unrecognized Tax Benefits: Gross unrecognized tax benefits of $4.4 million as of December 31, 2025, with accrued interest and penalties of $1.5 million.